Furthermore, alongside the increasing prevalence of related cardiometabolic diseases such as diabetes, obesity and chronic kidney disease (CKD), the number of people with HF has increased to around 64 million globally, amongst whom most are also living with type 2 diabetes or obesity ( Within the past 2 decades, glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) have emerged as effective agents to improve glycaemic control in type 2 diabetes and to reduce body weight in people with overweight or obesity (Sattar et al., 2021
Serious adverse events appeared in 9.8% of the combination group, including two deaths (one suicide, one cancer)
Weight regain patterns Clinical data from GLP-1 receptor agonist discontinuation studies consistently shows weight regain after stopping treatment
For laboratories and independent researchers, understanding the nuances of the GLP-1 research peptide is essential for maintaining experimental integrity and achieving reproducible data
Firstly, causality could not be established because the study was a cross-sectional analysis
The preservatives in the formulation, typically benzyl alcohol or phenol, are designed to handle some level of contamination
